» Articles » PMID: 10217653

Infective Endocarditis in Hypertrophic Cardiomyopathy: Prevalence, Incidence, and Indications for Antibiotic Prophylaxis

Overview
Journal Circulation
Date 1999 Apr 27
PMID 10217653
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The literature on infective endocarditis in hypertrophic cardiomyopathy (HCM) is virtually confined to case reports. Consequently, the risk of endocarditis in HCM remains undefined.

Methods And Results: We assessed the occurrence of endocarditis in 810 HCM patients evaluated between 1970 and 1997. Endocarditis was diagnosed in 10 patients, 2 of whom were excluded from analysis of prevalence and incidence because they were referred for acute endocarditis. At first evaluation, echocardiographic features consistent with prior endocarditis were identified in 3 of 808 patients, a prevalence of 3.7 per 1000 patients (95% CI, 0.8 to 11). Of 681 patients who were followed, 5 developed endocarditis, an incidence of 1.4 per 1000 person-years (95% CI, 0.5 to 3.2); outflow obstruction was present in each of these 5 patients and was associated with the risk of endocarditis (P=0.006). In the 224 obstructive patients, incidence of endocarditis was 3.8 per 1000 person-years (95% CI, 1.6 to 8.9) and probability of endocarditis 4. 3% at 10 years. Left atrial size was also associated with the risk of endocarditis (P=0.007). In patients with both obstruction and atrial dilatation (>/=50 mm), incidence of endocarditis increased to 9.2 per 1000 person-years (95% CI, 2.5 to 23.5). Analysis of all 10 patients with endocarditis identified outflow obstruction in each and atrial dilatation in 7.

Conclusions: Endocarditis in HCM is virtually confined to patients with outflow obstruction and is more common in those with both obstruction and atrial dilatation. These results indicate that antibiotic prophylaxis is required only in patients with obstructive HCM.

Citing Articles

Incidence of infective endocarditis in patients with hypertrophic cardiomyopathy.

Somendra S, Mehrotra S, Barwad P, Gupta H, Bahl A Indian Heart J. 2024; 76(6):405-407.

PMID: 39586399 PMC: 11705623. DOI: 10.1016/j.ihj.2024.11.332.


Complexities of Infective Endocarditis in a Young Patient With Hypertrophic Obstructive Cardiomyopathy: A Case of Dual Valve Involvement and Neurological Complications.

Yetiskul E, Hussain M, Khan D, Khan S, Spagnola J Cureus. 2024; 16(4):e57437.

PMID: 38699093 PMC: 11063810. DOI: 10.7759/cureus.57437.


Clinical profile and outcomes of pediatric hypertrophic cardiomyopathy in a South Indian tertiary care cardiac center: a three decade experience.

Mukhtar G, Sasidharan B, Krishnamoorthy K, Kurup H, Gopalakrishnan A, Sasikumar D BMC Pediatr. 2023; 23(1):446.

PMID: 37679699 PMC: 10483701. DOI: 10.1186/s12887-023-04255-z.


Infective Endocarditis in Hypertrophic Obstructive Cardiomyopathy After Etonogestrel Implant Removal.

Dlewati M, Harrisingh K, Dabiri R Cureus. 2022; 14(10):e29810.

PMID: 36337782 PMC: 9621098. DOI: 10.7759/cureus.29810.


Mitral Valve Perforated Aneurysm: An Issue of Inflammation or Pressure Gradients?.

Oliveira I, Cruz I, Neto A, Braganca B, Abreu G, Azevedo J Arq Bras Cardiol. 2022; .

PMID: 36228278 PMC: 9750205. DOI: 10.36660/abc.20211031.